Sanofi-Pasteur H5N1 Avian Flu Vaccine Stimulates Immune Response In Trial
This article was originally published in The Pink Sheet Daily
The 300-subject study showed that a regimen of two 30 mcg doses with adjuvant was safe and well tolerated.
You may also be interested in...
Accelerated review of flu vaccine “core dossiers” would allow approval within days of strain identification.
The number of viable doses will depend upon the outcome of ongoing dosing studies, HHS says.
Roche will consider requesting a re-examination of the negative decision by the Committee for Medicinal Products for Human Use.